UOC
CRGX

UBS O'Connor’s CARGO Therapeutics CRGX Stock Holding History

UBS O'Connor’s Portfolio CRGX Stock Details CRGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26,899
Closed -$388K – 368
2024
Q4 		$388K Buy
26,899
+4,851
+22% +$88K 0.01% 301
2024
Q3 		$407K Buy
22,048
+2,048
+10% +$36.6K 0.01% 356
2024
Q2 		$328K Buy
+20,000
New +$380K 0.01% 391

Other funds holding CRGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $136M AUM 328.39% 1-Year Est. Return

UBS O'Connor's CRGX Position: Q1 2025 in Review

UBS O'Connor sold out of CARGO Therapeutics (CRGX) in Q1 2025, closing a stake of 26,899 shares — an estimated $388K sold.

UBS O'Connor first reported a position in CRGX in Q2 2024 and held it in 3 quarters. The position peaked at $407K in Q3 2024. 113 funds tracked by Wall St. Rank hold CRGX as of Q1 2025.

  • UBS O'Connor reported no remaining CARGO Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 26,899 CARGO Therapeutics shares in Q1 2025, an estimated $388K.
  • UBS O'Connor first reported a position in CARGO Therapeutics in Q2 2024 and held it in 3 quarters.
  • UBS O'Connor's CARGO Therapeutics position peaked at $407K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held CARGO Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.